CD4 is the foundation
TaiMed has spent nearly two decades developing, validating, and extending a CD4-targeted antibody approach. The CD4 receptor is central to HIV entry, making it a distinct host-cell target for therapeutic intervention. That biology connects TaiMed's commercial product, lead clinical program, and next-generation research.Why CD4?
HIV uses the CD4 receptor on helper T cells as a primary point of entry into the host cell. Many antiretroviral therapies act directly on viral proteins. TaiMed's CD4-targeted antibodies intervene at the host-cell level, creating a mechanism that is not exposed to the same viral mutational dynamics as therapies directed only at the virus.💡A differentiated resistance framework
By targeting a conserved host-cell structure, CD4-directed therapy introduces a mechanistically distinct approach that may complement virus- directed antiretroviral classes.
By targeting a conserved host-cell structure, CD4-directed therapy introduces a mechanistically distinct approach that may complement virus- directed antiretroviral classes.
A clinically validated foundation
TaiMed's CD4-targeted approach was clinically and regulatorily validated through Trogarzo® (ibalizumab-uiyk), the first FDA-approved monoclonal antibody for HIV treatment. Trogarzo established proof that a CD4-directed post-attachment inhibitor could be developed, approved, manufactured, and commercialized for people living with HIV.Next-generation CD4 targeting
TMB-365 is a second-generation evolution of ibalizumab science. It was engineered to preserve CD4 targeting while improving viral-strain coverage and extending exposure to support long-acting development. TMB-365 is the host-targeting component of TaiMed's lead TMB-365/380 program and may also provide a complementary component for future long-acting HIV combinations.A complementary host-and-virus strategy
TMB-365/380 brings together two long-acting antibodies with distinct mechanisms. TMB-365 binds the CD4 receptor on host T cells and blocks post-attachment HIV entry. TMB-380 (VRC07-523LS) is a broadly neutralizing antibody that targets the conserved CD4-binding site on HIV-1 gp120. Together, the regimen is designed to address both the host cell and the virus.
TMB-365 | Host target
Binds CD4 on host T cells and blocks the post-attachment step required for HIV entry.
TMB-380 | Viral target
Binds the CD4-binding site on HIV-1 gp120, providing a complementary virus-directed mechanism.
Extending CD4-targeted delivery
TaiMed is also exploring how TMB-365 can serve as a targeting vehicle for antibody-drug conjugates. In HIV cure research, the goal is to deliver therapeutic payloads selectively to CD4+ cells associated with the latent viral reservoir. The same targeting concept is being explored in other immune-directed areas where dysregulated CD4+ T cells contribute to disease.Preclinical research. Safety and efficacy have not been established.
Contact CDMO Service